Works matching Progesterone antagonists


Results: 494
    1
    2
    3
    4
    5
    6
    7
    8
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

    Published in:
    Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-022-01063-5
    By:
    • Bartlett, Thomas E.;
    • Evans, Iona;
    • Jones, Allison;
    • Barrett, James E.;
    • Haran, Shaun;
    • Reisel, Daniel;
    • Papaikonomou, Kiriaki;
    • Jones, Louise;
    • Herzog, Chiara;
    • Pashayan, Nora;
    • Simões, Bruno M.;
    • Clarke, Robert B.;
    • Evans, D. Gareth;
    • Ghezelayagh, Talayeh S.;
    • Ponandai-Srinivasan, Sakthivignesh;
    • Boggavarapu, Nageswara R.;
    • Lalitkumar, Parameswaran G.;
    • Howell, Sacha J.;
    • Risques, Rosa Ana;
    • Rådestad, Angelique Flöter
    Publication type:
    Article
    33

    Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

    Published in:
    Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-022-01063-5
    By:
    • Bartlett, Thomas E.;
    • Evans, Iona;
    • Jones, Allison;
    • Barrett, James E.;
    • Haran, Shaun;
    • Reisel, Daniel;
    • Papaikonomou, Kiriaki;
    • Jones, Louise;
    • Herzog, Chiara;
    • Pashayan, Nora;
    • Simões, Bruno M.;
    • Clarke, Robert B.;
    • Evans, D. Gareth;
    • Ghezelayagh, Talayeh S.;
    • Ponandai-Srinivasan, Sakthivignesh;
    • Boggavarapu, Nageswara R.;
    • Lalitkumar, Parameswaran G.;
    • Howell, Sacha J.;
    • Risques, Rosa Ana;
    • Rådestad, Angelique Flöter
    Publication type:
    Article
    34

    Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

    Published in:
    Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-022-01063-5
    By:
    • Bartlett, Thomas E.;
    • Evans, Iona;
    • Jones, Allison;
    • Barrett, James E.;
    • Haran, Shaun;
    • Reisel, Daniel;
    • Papaikonomou, Kiriaki;
    • Jones, Louise;
    • Herzog, Chiara;
    • Pashayan, Nora;
    • Simões, Bruno M.;
    • Clarke, Robert B.;
    • Evans, D. Gareth;
    • Ghezelayagh, Talayeh S.;
    • Ponandai-Srinivasan, Sakthivignesh;
    • Boggavarapu, Nageswara R.;
    • Lalitkumar, Parameswaran G.;
    • Howell, Sacha J.;
    • Risques, Rosa Ana;
    • Rådestad, Angelique Flöter
    Publication type:
    Article
    35
    36
    37
    38

    Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

    Published in:
    PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0204973
    By:
    • Cottu, Paul H.;
    • Bonneterre, Jacques;
    • Varga, Andrea;
    • Campone, Mario;
    • Leary, Alexandra;
    • Floquet, Anne;
    • Berton-Rigaud, Dominique;
    • Sablin, Marie-Paule;
    • Lesoin, Anne;
    • Rezai, Keyvan;
    • Lokiec, François M.;
    • Lhomme, Catherine;
    • Bosq, Jacques;
    • Bexon, Alice S.;
    • Gilles, Erard M.;
    • Proniuk, Stefan;
    • Dieras, Veronique;
    • Jackson, David M.;
    • Zukiwski, Alexander;
    • Italiano, Antoine
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46

    Clinical applications of mifepristone.

    Published in:
    Gynecological Endocrinology, 2006, v. 22, n. 12, p. 655, doi. 10.1080/09513590601005946
    By:
    • Tang, Oi Shan;
    • Ho, Pak Chung
    Publication type:
    Article
    47
    48
    49
    50